DNA topoisomerase II in therapy-related acute promyelocytic leukemia. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Adès L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Chomienne C, Solomon E, Fenaux P, Grimwade D (2005) N Engl J Med 352: 1529-38 Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D, Bunin GR, Meadows AT (2000) J Clin Oncol 18: 12-7 Etoposide kinetics in patients with obstructive jaundice. Hande KR, Wolff SN, Greco FA, Hainsworth JD, Reed G, Johnson DH (1990) J Clin Oncol 8: 1101-7 Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M (1993) J Clin Oncol 11: 22-8 Bioavailability of low-dose oral etoposide. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH (1993) J Clin Oncol 11: 374-7 Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA (1992) J Clin Oncol 10: 292-6 Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. Rodenhuis S, Boerrigter L, Top B, Slebos RJ, Mooi WJ, van't Veer L, van Zandwijk N (1997) J Clin Oncol 15: 285-91 Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD (1990) J Clin Oncol 8: 1613-7 Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA (1993) J Clin Oncol 11: 1322-8 Copy number polymorphisms and anticancer pharmacogenomics. Gamazon ER, Huang RS, Dolan ME, Cox NJ (2011) Genome Biol 12: R46 A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME (2007) Proc Natl Acad Sci U S A 104: 9758-63 Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Lovett BD, Lo Nigro L, Rappaport EF, Blair IA, Osheroff N, Zheng N, Megonigal MD, Williams WR, Nowell PC, Felix CA (2001) Proc Natl Acad Sci U S A 98: 9802-7 Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH (1997) Blood 90: 935-43 Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide. DeVore RF, Corbett AH, Osheroff N (1992) Cancer Res 52: 2156-61 Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C (2007) Cancer Res 67: 1176-83 Caspase-cleaved arrestin-2 and BID cooperatively facilitate cytochrome C release and cell death. Kook S, Zhan X, Cleghorn WM, Benovic JL, Gurevich VV, Gurevich EV (2014) Cell Death Differ 21: 172-84 Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II. Baldwin EL, Berger AC, Corbett AH, Osheroff N (2005) Nucleic Acids Res 33: 1021-30 Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks. Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N (2003) Nucleic Acids Res 31: 4373-84 Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides. Duca M, Guianvarc'h D, Oussedik K, Halby L, Garbesi A, Dauzonne D, Monneret C, Osheroff N, Giovannangeli C, Arimondo PB (2006) Nucleic Acids Res 34: 1900-11 The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Hande KR (1996) Stem Cells 14: 18-24 Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L (2017) Ann Oncol 28: 777-783 E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW (1997) Mol Cell Biol 17: 1049-56 Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study. Thompson DS, Hainsworth JD, Hande KR, Holzmer M, Greco FA (1994) Cancer 73: 2824-31 A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Murphy PB, Hainsworth JD, Greco FA, Hande KR, DeVore RF, Johnson DH (1992) Cancer 69: 370-5 Current status of etoposide in the management of small cell lung cancer. Johnson DH, Hainsworth JD, Hande KR, Greco FA (1991) Cancer 67: 231-44 A randomized Phase II trial in patients with carcinoma of an unknown primary site. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR (2001) Cancer 91: 592-7 Etoposide: four decades of development of a topoisomerase II inhibitor. Hande KR (1998) Eur J Cancer 34: 1514-21 Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N (1991) J Biol Chem 266: 14585-92 Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. Corbett AH, Hong D, Osheroff N (1993) J Biol Chem 268: 14394-8 A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. Hsiung Y, Elsea SH, Osheroff N, Nitiss JL (1995) J Biol Chem 270: 20359-64 Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (1999) J Biol Chem 274: 35927-32 Apurinic sites are position-specific topoisomerase II poisons. Kingma PS, Osheroff N (1997) J Biol Chem 272: 1148-55 Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, Osheroff N (1996) J Biol Chem 271: 29238-44 Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity. Fortune JM, Lavrukhin OV, Gurnon JR, Van Etten JL, Lloyd RS, Osheroff N (2001) J Biol Chem 276: 24401-8 A two-drug model for etoposide action against human topoisomerase IIalpha. Bromberg KD, Burgin AB, Osheroff N (2003) J Biol Chem 278: 7406-12 Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells. Carrillo AM, Hicks M, Khabele D, Eischen CM (2015) Mol Cancer Res 13: 1197-205 Etoposide pharmacology. Hande KR (1992) Semin Oncol 19: 3-9 Combination chemotherapy with oral etoposide. Johnson DH, Hainsworth JD, Hande KR, Greco FA (1992) Semin Oncol 19: 19-24 Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial. Johnson DH, DeVore R, Greco FA, Walls J, Thomas M, Hande KR, Hainsworth JD (1992) Semin Oncol 19: 50-6 Cleavage of arrestin-3 by caspases attenuates cell death by precluding arrestin-dependent JNK activation. Kook S, Vishnivetskiy SA, Gurevich VV, Gurevich EV (2019) Cell Signal 54: 161-169
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.